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We have recently shown that cultures of human blood mononuclear cells stimu-
lated with Escherichia coli LPS or PHA produce a 70 amino acid neutrophil-activating
peptide, termed NAP-2,' which appears to be a cleavage product of the platelet
a-granule component platelet basic protein (PBP) and its derivative, connective tis-
sue-activating peptide III (CTAP-III) (1). NAP-2 has similar size and marked se-
quence homology to other recently described inflammatory peptides, NAF/NAP-1
(2) and the murine protein MIP-2 (3). Unlike its presumed precursors, PBP and
CTAP-III, NAP-2 has powerful neutrophil-stimulating effects and a profile of bio-
logical activity similar to that of NARNAP-1 (4).
We have now studied the conditions for the generation of NAP-2. This article shows
that platelets are the source of the precursor proteins and that proteases secreted
from monocytes process these proteins into neutrophil-activating peptides.
Materials and Methods
Media and Solutions.
￿
Two culture media were used, MEM and MEM-PPL. MEM con-
sisted of Eagle's MEM (Seromed GmbH, Munich, FRG) supplemented with 25 Rg/ml neo-
mycin and buffered at pH 7.4 with 25 mM NaHC03 and 20 mM HEPES. MEM-PPL con-
tained in addition 1% pasteurized plasma protein solution (5% PPL SRK; Swiss Red Cross
Laboratory, Bern, Switzerland) and 100 IU/ml penicillin/streptomycin (Gibco). Recombinant
NAF/NAP-1 was obtained from the Sandoz-Forschungsinstitut GmbH, Vienna, Austria (5).
Cell Preparations.
￿
Monocytes (90% pure) and lymphocytes (95% pure) were obtained from
buffy coats of donor blood by centrifugation on Ficoll-Paque followed by centrifugal elutria-
tion (6). Neutrophils were isolated and used exactly as described previously (6) and platelets
were prepared from platelet-rich plasma (7).
Cell Cultures.
￿
Monocytes (1.2 x 105 cells/cm2) and lymphocytes (2.3 x 106 cells/cm2) were
cultured in 175-cm2 flasks with 100 ml MEM-PPL for 22 h at 37°C in a 5% C02 atmosphere
in the presence of the release supernatant from 2 x 10"' thrombin-stimulated platelets (4).
Three different stimuli, 1 lug/ml LPS (LPS from E. coli 055 :B5; Difco Laboratories, Basel,
Switzerland), 5 lag/ml PHA (Difco) were used.
Purification ofAptides.
￿
Monocyte and lymphocyte culture supernatants (95 ml) were passed
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through 5-ml phosphocellulose columns (Whatman Pll) equilibrated in 20 mM potassium
phosphate, pH 7.2, 20 mM NaCl, 1 mM EDTA, and 5% glycerol at room temperature. The
columns were washed with 10 ml equilibration buffer and 10 ml ofthe same buffer supplemented
with 0.2 M NaCl. Elution was performed with three 3-ml portions of equilibration buffer
supplemented with 1.2 M NaCl. Fractions with neutrophil-stimulating activity (kept at 4°C)
were acidified with trifluoroacetic acid (TFA) and directly loaded onto an analytical HPLC
reversed-phase cyanopropyl column, (4.6 x 250 mm, 5 gm, wide-pore; Baker Research Prod-
ucts, Phillipsburg, NJ). The column was eluted at 0.5 ml/min with a gradient ofacetonitrile
in 0.1% TFA with an increment of 0.66%/min. 1-min fractions were collected and tested for
neutrophil-stimulating activity.
Processing of CTAPH1 to NAP-2.
￿
About 10" monocytes were cultured for 22 h in 200 ml
MEM-PPL. The culture supernatant was cleared by centrifugation (20,000 g for 20 min)
and concentrated 50-fold by means ofCX-10 ultrafilters (Millipore, Bedford, MA). Aliquots
of 20 1A of the concentrate were incubated with 5,ug of CTAP-III, purified as described (4),
for up to 16 h at 37°C in a total volume of 1 ml PBS containing 1% PPL. PMSF (Fluka),
leupeptin (Fluka AG, Buchs, Switzerland), or EDTA were added as potential inhibitors.
Bioassay.
￿
A microtiter plate fluorescence assay for elastase release was used to assess neu-
trophil activation (4).
AminoAcid SequenceAnalysis.
￿
This was performed by automated phenyl isothiocyanate degra-
dation with a gas phase sequencer (No. 477 A; Applied Biosystems, Inc., Foster City, CA).
Samples of the purified peptides (500 pmol) were applied directly or after chemical modification.
Reduction and alkylation was performed as described (1).
Results
Source ofNAP-2.
￿
The formation of NAP-2 and other neutrophil-stimulating pep-
tides was studied with purified populations of monocytes and lymphocytes stimu-
lated in different ways in the presence and absence of platelet release supernatant
containing PBP and CTAP-III . Before biological testing, the conditioned medium
was fractionated by cation-exchange chromatography followed by reversed-phase
HPLC, resolving three peaks of activity with mean modal retention times of about
22, 26, and 34 min. Sequencing of the material recovered showed that peak 1 cor-
responded to NAP-2 (70 amino acids), peak 2 to a mixture of three NAP-2 variants
with 73, 74, and 75 residues, and peak 3 to NAF/NAP-1 (Fig. 1).
Fig. 2 illustrates the role of monocytes in NAP-2 production. NAP-2 was produced
whenever monocytes were cultured in the presence of platelet-release supernatant
(Exps. C-E), but not when either the cells or the supernatant were omitted (Exps .
A and B). When PHA or LPS were added as stimulus, NAF/NAP-1 was also pro-
duced and accounted for a major portion of the total neutrophil-stimulating activity.
Stimulation of the monocytes and production of NAF/NAP-1 did not influence the
yield of NAP-2, as shown by the comparison of Exp. C with Exps. D and E. Upon
stimulation with LPS, however, a somewhat smaller intermediate peak containing
NAP-2 (70)
￿
Ala-Glu-Leu-Arg-Cys-Met-Cys-Ile-Lys . . .
(75) Asp-Ser-Asp-Leu-Tyr-Ala-Glu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(74) Ser-Asp-Leu-Tyr-Ala-Glu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
(73) Asp-Leu-Tyr-Ala-Gla. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
NAP-1 (72)
￿
Ser-Ala-Lys-Glu-Leu-Arg-Cys-Gln-Cys-Ile-Lys . . .
FIGURE 1. NAP-2 and its
NHz-terminal variants with
neutrophil-stimulating activity;
comparison with NAF/NAP-1.
The sequences are aligned ac-
cording to the conserved cys-
teine residues and the total
number ofresidues is indicated
in brackets.WALZ AND BAGGIOLINI
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FIGURE 2 .
￿
Neutrophil-activating peptides pro-
duced by cultured human blood monocytes . Cul-
ture supernatants were harvested after 22 h and
chromatographed as described in Materialsand
Methods . Histograms representing the distribu-
tion of neutrophil-stimulating activity (fluores-
cence measurement of elastase release) versus
retention time on reversed-phase HPLC are
shown . The experimental conditions were : (A)
platelet-release supernatant (PR) in the absence
ofcells ; (B) LPS-stimulated monocytes in the ab-
sence ofPR ; (C) unstimulated monocytes in the
presence ofPR, (D) PHA-stimulated monocytes
in the presence ofPR, (E) LPS-stimulated mono-
cytes in the presence ofPR. The three peaks of
activity seen in lane E are : NAP-2 (21.8 min),
NAP-2 variants (26.2 min),andNAF/NAP-1(34 .6
min) . The data are representative for two (A)and
five (B-E) similar experiments .
the 73-75 residue variants of NAP-2 was obtained in addition . As estimated from
the sequencing data, the additional peak was made up to 65, 20, and 15% by the
74, 75, and 73 residue form, respectively.
Similar experiments were performed with lymphocytes instead ofmonocytes . As
shown in Fig . 3, Exps . C-E, neither NAP-2 nor NAF/NAP-1 were produced by stimu-
lated or unstimulated lymphocytes in the presence of platelet release supernatant .
Exps . A and B illustrate the stimulus-dependent production ofNAF/NAP-1 bymono-
cytes and the lack of production of NAP-2 when the platelet-release supernatant
is omitted .
Cellfree Generation ofNAP-2.
￿
The presumed role ofmonocyte proteases in the gener-
ation of NAP-2 was studied in cell-free assays using purified CTAP-III as the sub-
strate. In preliminary experiments it was established that at least 80% of the total
CTAP-III cleaving activity of 22-h cultures of purified monocytes was recovered in
the medium (data not shown), indicating that the processing enzymes are secreted
by the monocytes and are not appreciably stored intracellularly . The time course
and inhibition ofNAP-2 formation (detected as neutrophil-stimulating activity) were
FIGURE 3 .
￿
Lack of production of neutrophil-
activating peptides by cultured humanblood lym-
phocytes . Culture conditions andhistograms as
in Fig . 2 . The experimental conditions were : Un-
stimulated (A) and LPS-stimulated (B) monocytes
in the absence ofplatelet release supernatant ; un-
stimulated (C), PHA-stimulated (D), and LPS-
stimulated (E) lymphocytes in the presence of
platelet-release supernatant. The data are rep-
resentative for three similar experiments.452
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therefore studied using purified CTAP-III and concentrated monocyte conditioned
medium (see Materials and Methods).
As shown in Fig. 4, a linear increase in NAP-2 formation was obtained in the
presence of CTAP-III and the conditioned medium, while no change was observed
when either one ofthe reactants were omitted. CTAP-III alone showed no activity,
confirming our earlier observations (4), while a low, constant background was de-
tected with medium alone, which could be attributed to NAF/NAP-1, on the basis
ofinactivation with an antiserum. Similarexperiments were performed inthe pres-
ence of inhibitors. NAP-2 formation was almost totally suppressed by PMSF but
was not affected by EDTA, suggesting thatthe conversion was largely due to a serine
protease. Leupeptin, athiol-proteinaseinhibitor, had a moderate but consistent effect,
and no NAP-2 formation was obtained when PMSF and leupeptin were combined
(not shown). While excluding a role for metallo-proteases, these experiments sug-
gest that CTAP-III conversion to neutrophil-activating peptides is probably due to
more than one enzyme.
Neutrophil Stimulation.
￿
The potency ofthe different peptides in inducing elastase
release is compared in Fig. 5. In agreement with former observations (1, 4), NAP-2
was active inthesameconcentration range, butwasabouthalfaspotent as NAF/NAP-1.
An at least 10-fold higher threshold concentration was observed for the mixture of
the 73-75 residue NAP-2 variants that were markedly less potent than NAP-2. The
same ranking was obtained when the rise in cytosolic free calcium was measured
(data not shown).
Discussion
The present study demonstrates that the neutrophil-activating peptide NAP-2 is
generatedfrom the platelet a-granule precursors, PBP andCTAP-III, through pro-
teases released from monocytes. Lymphocytes have no role in NAP-2 production,
and no NAP-2 is obtainedwhen the monocytes are cultured inthe absence ofplatelets
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FIGURE 4.
￿
(A) Generation of neutrophil-stimulating activity (elastase release) from CTAP-
III by monocyte-conditioned medium. CTAP-III alone (A), conditioned medium alone (0),
andCTAP-III plus conditioned medium (*). (B) Inhibition ofCTAP-III processing. CTAP-111
and conditioned medium were incubatedwith the followingadditions: none (*), 4 mM EDTA
(A), 50,u~/ml leupeptin (O), 2 mM PMSF (0). Each assay contained the medium equivalent
of 5 x 10 unstimulated monocytes cultured for 22 h, and 5 Wg of purified CTAP-III. Controls
showed that the neutrophil-activation assay was not influenced by the inhibitors used. Similar
data were obtained in four different experiments.U
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FIGURE 5.
￿
Neutrophil activation by
recombinant NAF/NAP-1 (A), NAP-
2 (O), and NAP-2 variants (0). Concen-
tration-dependent induction of elastase
release (fluorescence units) from cyto-
chalasin B- treated human neutro-
phils. The data are representative for
three similar experiments.
or platelet-release supernatant, even under stimulatory conditions leadingto the gener-
ation of high amounts of NAF/NAP-1.
Two platelet-derived fractions with neutrophil-stimulating activity were identified
in this study, one corresponding to NAP-2 and the other consisting of a mixture
ofthree slightly larger variants. Thelatter were obtained with stimulated mononuclear
phagocytes only, while the yield of NAP-2 was not influenced by stimulation . These
observations suggest that different proteases or peptidases are involved in the forma-
tion ofthe two active fractions, andthat theNAP-2 variants are not obligatory inter-
mediates of NAP-2 formation. CTAP-III was used to studythe generation of NAP-2
by monocyte-conditioned media since its concentration in platelet release superna-
tants is usually higher than that of PBP (8). From the effects of inhibitors, serine
and thiol proteases appear to be involved. These enzymes are likely to be released
constitutively by cultured monocytes (asstimulation did notenhance NAP-2 forma-
tion) andto act in concert sinceneither PMSF norleupeptin alone were fully inhibitory.
The NAP-2 variants were considerably less potent than NAP-2. The fact that no
peptide with less than 70 residues was identified, and that effectiveness decreased
rapidly with NH2-terminal elongation indicates that among the cleavage products
of CTAP-III NAP-2 may be the one with highest neutrophil-stimulating activity.
In terms of its biological effects on neutrophils, NAP-2 is similar to NAF/NAP-1.
Both peptides induce a transient rise in cytosolic free calcium, chemotaxis, and exo-
cytosis in the lower micromolar concentration range (4), and thus qualify as patho-
physiologically relevant inflammatory mediators. Neither peptide is generated con-
stitutively. The production of NAF/NAP-1 (by mononuclearphagocytes and a wide
variety of tissue cells [2]) is induced by inflammatory cytokines like TNF and IL-1,
whileNAP-2, as this studyindicates, canonly be generated when PBPand/or CTAP-III
are liberated from platelets. Despite theirfunctional similarity, the two peptides must,
therefore, be expected to arise in dissimilar pathological situations and at different
sites. Being platelet derived, NAP-2 will be produced mainly intravascularly, where
platelet activation and aggregation occurs, e.g., in thrombi and atherosclerotic le-
sions (4), while NAF/NAP-1 will almost invariably form in the tissues (2).
Summary
We studied the origin of the neutrophil-activating peptide NAP-2, a presumed
70 amino acid cleavage product of platelet basic protein (PBP) and connective454 PLATELET-DERIVED NEUTROPHIL-ACTIVATING PEPTIDE NAP-2
tissue-activating peptide III (CTAP-III) . Purified human blood monocytes or lym-
phocytes were cultured with or without stimuli (LPS or PHA) in the presence or
absence of platelet-release supernatant, and the formation of NAP-2 and other
neutrophil-activating peptides was monitored. NAP-2 was generated whenever mono-
cytes and platelet release supernatant were present. When a monocyte stimulus was
added, NAF/NAP-1 was also formed, and in the presence of LPS a third, less potent
neutrophil-stimulating fraction, consisting of NAP-2 variants with 73, 74, and 75
residues, also appeared. Monocytes alone did not yield NAP-2 and no neutrophil-
activating peptide was generated by lymphocytes. The monocyte-conditioned medium
was found to cleave purified CTAP-III into NAP-2 through proteinases that were
highly sensitive to PMSF, moderately sensitive to leupeptin and insensitive to EDTA.
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